EEM Fest Cardiogenic Shock: Pitfalls to Avoid

Cardiogenic shock is a low-perfusion emergency where hypoxemia, high work of breathing, and pump failure can spiral quickly. Early noninvasive ventilation, bedside ultrasound volume assessment, norepinephrine support, and rapid cause-finding are the core moves in emergency management.

Cardiogenic Shock Initial Management

• Early NIPPV strategy: High work of breathing worsens myocardial oxygen demand, so noninvasive ventilation is the first stabilizing move; starting around EPAP 5 cm H2O can unload the patient without stealing too much preload.
• Pre-intubation stabilization: If possible, resuscitate before intubation because induction can precipitate collapse in severe cardiogenic shock. We get into the practical airway sequencing in the episode.
• POCUS volume assessment: Bedside ultrasound is the key fork in the road: a full IVC and loaded RV push you toward pressure support, while a flat IVC can justify cautious 250 mL fluid boluses.
• Mottling as red flag: Cool mottled extremities are a poor prognostic sign and a bedside clue to inadequate end-organ perfusion, even before labs fully declare how sick the patient is.
• Norepinephrine first pressor: Norepinephrine is the blood-pressure workhorse in cardiogenic shock, with a practical target of at least MAP 60 while you confirm the physiology and organize definitive treatment.
• Arterial line accuracy: Peripheral vasoconstriction makes cuff pressures unreliable in shock, so an arterial line gives cleaner hemodynamics and safer titration when vasoactive support is changing quickly.

Finding The Cause And Escalating Support

• Ischemia as leading cause: Acute cardiac ischemia drives roughly 75% of cardiogenic shock, making aspirin, antiplatelet therapy, anticoagulation, and especially early PCI the highest-yield cause-directed priorities.
• Sepsis overlap physiology: Septic and cardiogenic shock can coexist, so if infection is plausibly on the table, send cultures early and start broad-spectrum antibiotics rather than anchoring on a single phenotype.
• Diuresis timing caution: Pulmonary edema does not automatically mean early diuresis; the hypotensive patient in cardiogenic shock often cannot tolerate it until perfusion is restored.
• Dobutamine perfusion endpoints: Dobutamine is for persistent low-output signs despite an acceptable MAP, but it can drop blood pressure; titrate to perfusion markers like urine output, mental status, and lactate trend.
• Mechanical bridge options: IABP, LVAD, and ECMO are bridge therapies when standard measures are failing, with ECMO showing a possible mortality benefit in selected patients. We cover where these fits start to matter on the show.

References:

1. Samsky MD, et al. Cardiogenic Shock After Acute Myocardial Infarction: A Review [published correction appears in JAMA. 2021 Dec 14;326(22):2333]. JAMA. 2021;326(18):1840-1850. PMID: 34751704
2. Tehrani BN, et al. A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock. JACC Heart Fail. 2020;8(11):879-891. PMID: 33121700
3. Vahdatpour C, Collins D, Goldberg S. Cardiogenic Shock. J Am Heart Assoc. 2019;8(8):e011991.  PMID: 30947630 https://emcrit.org/ibcc/chf/